|
|
Profile
|
Delegates :
Kenji Nonaka |
|
Incorporated :
April 9 , 2021 |
Paid in Capital :
Million yen |
Employees :
67 人 |
Address :
36-1 Yoshida-honmachi, Sakyoku, KYOTO
〒606-8317
|
TEL/FAX :
+81-70-7423-1047 / +81-466-23-6131 |
URL：
https://orizuru-therapeutics.com/en/ |
Attachment :
 OZTx_Corporate_Profile_EN_by_page_v3.0.pdf [ 999.2KiB ] |
Mission/Background :
Orizuru Therapeutics Inc., was established in 2021 as a spinout from Takeda Pharmaceuticals and Kyoto University. The underlying technology is based on innovations from induced pluripotent stem cell (iPSC) research. This company is an R&D-driven company developing iPSCs to cure life-threatening diseases with large unmet needs. Our current focuses are 1. Development of regenerative medical products through cell therapy, and 2. Provide service of iPSC related expertise to support drug discovery research. |
|
Technology & Business
|
OZTx-556, human iPSC-derived cardiomyocytes
OZTx-556 is highly engraftable, pure and safe cardiomyocytes, and the transplantation enables patients to replenish cardiomyocytes lost in heart diseases and promote remuscularization. We have confirmed the efficacy and safety in animal models and are preparing for clinical trials as a treatment for chronic heart failure.
OZTx-410, human iPSC-derived pancreatic islet cells
OZTx-410 is highly engraftable, pure and safe pancreatic cells, and the transplantation enables patients to form pancreatic islet structures and physiologically control blood glucose levels in severe diabetes. We have confirmed the efficacy and safety in animal models and are preparing for clinical trials as a treatment for brittle type I diabetes.
Platform innovation
We have an entrusted business to provide solution for customers who need technical support for experiments using iPS cells. Our experienced technical staffs can help you to generate quality data to advance your research.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
iPS cell-derived cardiomyocyte OZTx-556
|
Preclinical
|
●Long term efficacy, safety, and durability demonstrated in preclinical models●Phase 1 clinical trial is planned
|
Start of clinical trials
|
iPS cell-derived pancreatic islet cells OZTx-410
|
Preclinical
|
●Long term efficacy, safety, and durability demonstrated in preclinical models●Phase 1 clinical trial is planned
|
Start of clinical trials
|
Platform Innovation
|
Service/Marketing
|
Provide service of iPS cell-related expertise to support drug discovery research
|
Acquisition of new customers
|
|
|
|
|
|
|
|
|
|
Highlights
|
●ERRγ agonist under mechanical stretching manifests hypertrophic cardiomyopathy phenotypes of engineered cardiac tissue through maturation._Stem Cell Reports j Vol. 18 j 2108–2122 j November 14, 2023
●CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs_Stem Cell Research & Therapy volume 14, 1 2023
●Elimination of non-target cells mixed into islet-like cells generated from human iPS cells based on characterization_ Scientific Reports volume 12, 5221 2022
|
|
Alliance strategy
|
1. Seeking co-development or out-licensing opportunities for OZTx-556 and OZTx-410
2. Seeking collaboration or in-licensing opportunities for new preclinical assets or iPS cell-based technologies.
3. Seeking customers looking for outsourced lab services for drug discovery using iPS cells
|
|
|